Business Wire

PLANET

Share
Planet Joins ESA Third Party Mission Programme for Open Access to High-Frequency, High-Resolution Imagery

Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about Earth, today announced that Planet’s PlanetScope and SkySat data have joined the European Space Agency (ESA) Third Party Missions portfolio, enabling ESA to utilize Planet data for scientific, research, and pre-operational Earth Observation based applications development. Through distribution under the ESA Earthnet Programme , European researchers, scientists, and companies can access Planet’s high-frequency, high-resolution satellite data for non-commercial use.

Initiated in 1976, the ESA Earthnet Programme is a “Network for the Earth,” with the purpose of building an Earth Observation science community to acquire and share knowledge of our planet. Within this program, Planet joins more than 50 other missions owned by commercial or public organizations to add near-daily PlanetScope imagery , 50 cm SkySat imagery , and RapidEye archive data to this global network. In 2019, Planet entered into an agreement with ESA to evaluate making Planet’s data from its high-resolution constellation available as a Third Party Mission.

“We are very pleased to welcome PlanetScope and SkySat to ESA’s Third Party Missions portfolio and to begin the distribution of the Planet data through the ESA Earthnet Programme,” said Peggy Fischer, the Mission Manager of ESA Third Party Missions. “The high-resolution and high-frequency imagery from these satellite constellations will provide an invaluable resource for the European R&D and applications community, greatly benefiting research and business opportunities across a wide range of sectors.”

“Collaborating with ESA as part of the Earthnet Programme is the next step for Planet in our mission to image all of Earth’s landmass every day, making global change visible, accessible, and actionable”, said Charlie Candy, Planet’s Chief Revenue Officer. “It is fundamental that we empower the research community with transparent resources and knowledge for the benefit of all citizens.”

Planet’s work with partners through the ESA Earthnet Programme provides critical data to support the program’s ground-breaking work. Researchers and scientists are required to report their work and results after completion of their project through the program. The program was established with a goal to unleash a new set of uses and applications of Earth observation data to combat climate change and develop new capabilities in a variety of industries. The ESA TPM process includes the submission of a project proposal on the ESA Earth Online portal . To find out more on how to apply to the Earthnet Programme and get started with Planet data, join here .

About Planet Labs PBC

Planet is a leading provider of global, daily satellite imagery and geospatial solutions. Planet is driven by a mission to image the world every day, and make change visible, accessible, and actionable. Founded in 2010 by three NASA scientists, Planet designs, builds, and operates the largest Earth observation fleet of imaging satellites, capturing over 30 TB of data per day. Planet provides mission-critical data, advanced insights, and software solutions to over 700 customers, comprising the world’s leading agriculture, forestry, intelligence, education, and finance companies and government agencies, enabling users to simply and effectively derive unique value from satellite imagery. Planet is a public benefit corporation trading on the New York Stock Exchange as PL. To learn more visit www.planet.com and follow us on Twitter.

About ESA

The European Space Agency (ESA) provides Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. Learn more about ESA at www.esa.int .

Forward-looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s ability to capture market opportunity and realize any of the potential benefits from strategic partnerships and customer collaborations. Forward-looking statements are based on the Company’s management’s beliefs, as well as assumptions made by, and information currently available to them. Because such statements are based on expectations as to future events and results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to the risk factors and other disclosures about the Company and its business included in the Company's periodic reports, proxy statements, and other disclosure materials filed from time to time with the Securities and Exchange Commission (SEC) which are available online at www.sec.gov , and on the Company's website at www.planet.com . All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date such statements are made. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release

Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ

Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release

At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as

HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release

Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release

The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are

Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release

300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye